Rarebase

Rarebase is a public benefit corporation pioneering a new approach to biotech. We partner with patient organizations on translational therapeutic discovery and development.

Therapeutic development has to align with the needs of patients.

Rarebase is a public benefit corporation pioneering a new approach to biotech. We currently partner with over 15 patient organizations and families on translational therapeutic discovery and development.

We develop a liberated set of tools and resources to expedite therapeutic discovery.

The bottleneck for rare disease therapeutics is resource aggregation. ​Where gaps exist, we create new research assets - at cost and with extreme efficiency - and distribute them broadly to ensure that they are easily accessible to an organization’s entire scientific network.

We create a modality-agnostic research roadmap to get treatments to the clinic.

Leveraging our network of expert scientists, specialist laboratories, and leading biotechnology companies, we evaluate all feasible therapeutic approaches in parallel. We prioritize those that can be rapidly translated to the clinic regardless of future commercial upside.

The technology or drug to solve a disease may already be out there.

Our platform identifies intra-disease relationships that can benefit from similar or equal approaches or technologies. We continuously expand our knowledge base and know-how in every disease we are working on.